GlassScriptPhysician profile
Nikisha Ashok Kothari
NPI 1114366796
$12,395.24
in general payments reported to CMS, 2019-2025
11 companies · $18.55 in 2025
The $18.55 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $91.32 · 2021: $60.81 · 2022: $521 · 2023: $250 · 2024: $11K · 2025: $18.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,583 · Food and Beverage: $967 · Travel and Lodging: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,583.00 |
| Food and Beverage | $966.86 |
| Travel and Lodging | $795.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,612.78 | 2022-2024 | |
| Genentech USA, INC. | $2,341.49 | 2021-2024 | Vabysmo |
| Eyepoint US, INC. | $332.95 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $313.93 | 2019-2024 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $235.15 | 2019 | |
| Alimera Sciences, INC. | $165.76 | 2020-2024 | Iluvien, Yutiq |
| Coherus Oncology, INC. | $131.76 | 2022-2024 | |
| Ocular Therapeutix, INC. | $108.04 | 2024-2025 | Dextenza |
| Apellis Pharmaceuticals, INC. | $71.39 | 2023-2024 | Syfovre |
| Allergan, INC. | $57.91 | 2019-2021 | |
| Astellas Pharma US INC | $24.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikisha Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.